EYLEA – A Novel Drug for Retinal Diseases

EYLEA (Aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor developed by Regeneron Pharmaceuticals and Bayer for the treatment of various retinal diseases. It was approved by the US FDA in 2011 for treatment of wet age-related macular degeneration (AMD) and has since gained approval for other retinal conditions like diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO) and diabetic retinopathy (DR). EYLEA has emerged as a frontline drug owing to its superior efficacy compared to other anti-VEGF agents like Lucentis and Avastin. Let’s take a detailed look at EYLEA and its impact on global management of retinal diseases.

Global EYLEA Drug - A Breakthrough In Treatment Of Retinal Diseases -https://www.coherentmi.com/blog/global-eylea-drug-a-breakthrough-in-treatment-of-retinal-diseases-57